MUMBAI, India, Aug. 1 -- Intellectual Property India has published a patent application (202431005238 A) filed by Institute Of Life Sciences, Bhubaneswar, Odisha, on Jan. 25, 2024, for 'pharmaceutical composition for inhibition of dna polymerase kappa (polk).'
Inventor(s) include Soumen Chakraborty; Sumit Biswas; and Shristi Lama.
The application for the patent was published on Aug. 1, under issue no. 31/2025.
According to the abstract released by the Intellectual Property India: "The present invention relates to a pharmaceutical composition comprising 2-(2- chlorophenyl)-5-[6-phenoxy-4-(trifluoromethyl) pyridin-3-yl]-1,3,4-oxadiazole and MgCl2 as a DNA Polymerase Kappa inhibitor, methods of preparing them, and methods of treatment, prevention, and amelioration of DNA Polymerase Kappa-based diseases or disorders with them. The present invention also relates to a pharmaceutical composition comprising 2-(2-chlorophenyl)-5-[6-phenoxy-4-(trifluoromethyl) pyridin-3-yl]-1,3,4- oxadiazole, MgCl2, and an anti-cancer agent."
Disclaimer: Curated by HT Syndication.
